Back to Search
Start Over
The First-in-Class Alkylating Histone-Deacetylase Inhibitor (HDACi) Fusion Molecule Edo-S101 Exerts Potent Preclinical Activity Against Tumor Cells of Hodgkin Lymphoma (HL) Including Bendamustine-Resistant Clones
- Source :
- Blood; December 2015, Vol. 126 Issue: 23 p2481-2481, 1p
- Publication Year :
- 2015
-
Abstract
- Mehrling: 4Mundipharma-EDO GmbH, Basel, Switzerland: Employment. Pinto:Takeda, Celgene, Roche, TEVA: Honoraria; Takeda: Research Funding.
Details
- Language :
- English
- ISSN :
- 00064971 and 15280020
- Volume :
- 126
- Issue :
- 23
- Database :
- Supplemental Index
- Journal :
- Blood
- Publication Type :
- Periodical
- Accession number :
- ejs53051147
- Full Text :
- https://doi.org/10.1182/blood.V126.23.2481.2481